U.S. Biotech Stock News

In mid-January 2026, KeyBanc upgraded Materion to Overweight, citing expectations for stronger earnings supported by semiconductor, defense, and clean energy demand alongside margin enhancement initiatives. The upgrade underscores how Materion’s precision clad improvements and focus on higher-value materials could increase its appeal to growth-oriented investors. We’ll now examine how this upgrade, driven by anticipated semiconductor strength, may influence Materion’s existing investment...

On January 7, 2026, One Stop Systems, Inc. announced an approximately US$1.20 million pre-production order from a new U.S. defense prime contractor to design, develop, and deliver ruggedized GPU-accelerated compute and visualization systems for U.S. Army combat vehicles. This order deepens OSS’s role in next-generation Army vision and sensor programs by embedding its TSN- and PCIe-based architectures directly into a prime contractor’s system-level solution across multiple ground vehicle...

M&T Bank Corporation has released its full-year 2025 results, reporting net interest income of US$6,948 million, net income of US$2,851 million, and diluted earnings per share from continuing operations of US$17, alongside higher fourth-quarter net charge-offs of US$185 million. The combination of rising annual profitability and an uptick in credit losses gives investors a clearer view of how M&T Bank is balancing earnings strength with evolving credit risk. Next, we will examine how M&T...

Turning Point Brands (TPB) recently hit an all time high after stronger than expected third quarter results, higher full year guidance, an expanded US$200 million at the market program, and a maintained dividend. This has drawn fresh investor attention. See our latest analysis for Turning Point Brands. Those third quarter results and higher guidance arrived after a strong run, with the share price up 29.98% over 90 days and the 1 year total shareholder return at 109.8%, suggesting momentum...

Earlier in January 2026, Stoke Therapeutics said it had accelerated timelines for completing enrollment in its Phase 3 EMPEROR trial of zorevunersen for Dravet syndrome, aiming for a mid-2027 data readout to support a rolling New Drug Application to the US Food and Drug Administration. The update highlighted both strong global patient identification and ongoing FDA discussions about potential expedited regulatory pathways for a disease area that currently lacks approved disease-modifying...

In recent days, Texas Capital Bancshares reported record Q3 2025 earnings of US$2.18 per share with 12% year-over-year revenue growth, and authorized a new US$200.00 million share repurchase program for 2026. These results highlight the bank’s ability to convert its business initiatives into stronger profitability while returning excess capital directly to shareholders. Next, we’ll examine how the record quarterly earnings beat may influence Texas Capital Bancshares’ investment narrative and...

Medpace Holdings (MEDP) is drawing fresh attention after a strong price move that aligns with its operational metrics, including double digit revenue and net income growth and a high return on equity. See our latest analysis for Medpace Holdings. The recent move to a share price of $618.04 comes after a steady run, with a 30 day share price return of 10.61% and a 90 day gain of 17.04%. The 1 year total shareholder return of 83.49% and 5 year total shareholder return of 332.32% point to strong...

Initial context for OFG Bancorp OFG Bancorp (OFG) is back on investors’ radar after recent share price moves, with the stock closing at $41.92. That puts current performance in focus relative to its recent month and past 3 months returns. See our latest analysis for OFG Bancorp. The recent 1-day share price return of 1.6% follows a relatively steady year, with a year-to-date share price return of 2.2% and a 1-year total shareholder return close to flat. The 3 and 5 year total shareholder...

Recent commentary on Catalyst Pharmaceuticals highlights strong fundamental growth, healthy profitability, and solid financial footing in its rare disease franchise, with chart patterns pointing to a possible technical breakout setup identified prior to today, 16 January 2026. An interesting angle is that this combination of robust operating metrics and a potential technical breakout is drawing fresh investor attention to a company still trading at a relatively low earnings multiple versus...

Why the BAIC BJEV partnership matters for Pony AI (NasdaqGS:PONY) Pony AI (NasdaqGS:PONY) is back in focus after it formally expanded its cooperation with BAIC BJEV to push Level 4 robotaxis toward larger scale production, commercial use, and broader international deployment. The agreement spans vehicle design, supply chain, and fleet operations. It builds on Pony AI’s commercial Alpha T5 Robotaxi services in key Chinese cities and its stated ambition to reach markets such as the Middle East...

Trustmark (TRMK) has drawn fresh investor attention after announcing a partnership between Trustmark Bank and Greenlight Financial Technology, giving customers access to Greenlight's family finance app through the bank's digital channels. See our latest analysis for Trustmark. At a share price of $41.17, Trustmark has seen a 9.76% 90 day share price return and a 21.03% 1 year total shareholder return, which suggests momentum has been firming as investors react to initiatives like the...

NetApp, Inc. recently expanded its Board of Directors to ten members by appointing Paul Fipps, President of Global Customer Operations at ServiceNow, as an independent director, bringing more than 20 years of technology-enabled growth and customer transformation experience. His background in AI-focused digital transformation and customer-centric operations is particularly relevant as NetApp pursues its role as a provider of AI-ready data infrastructure and cloud-based services. We’ll now...

Recent earnings miss and rising questions on profitability ACV Auctions (ACVA) recently reported third quarter results that missed earnings and revenue forecasts, prompting analyst downgrades and new questions about its cost structure and path to sustainable profitability. Investors are weighing these weaker results against concerns over high servicing costs, low gross margins, and limited free cash flow. These factors are increasing pressure on the company to justify continued spending for...

Plexus recently saw increased investor interest after its strong Q4 2025 results, reported in October, topped earnings expectations and were followed by higher guidance for Q1 2026. The reaction has been led by institutions, which now hold more than 94% of the shares, with fresh buying from the State of Alaska's Department of Revenue underscoring growing institutional conviction. We'll now explore how this renewed institutional interest following Plexus's better-than-expected Q4 results may...

ARS Pharmaceuticals recently received approval from China’s National Medical Products Administration for neffy, its epinephrine nasal spray, and entered an exclusive commercialization agreement with Shanghai-based Pediatrix Therapeutics. This approval makes neffy the first epinephrine treatment cleared for community use outside hospitals in China, potentially reshaping ARS’s geographic and product diversification profile. We’ll now examine how China’s first-in-kind community-use approval for...

In early January 2026, Zenas BioPharma announced positive Phase 3 INDIGO trial results for obexelimab in patients with Immunoglobulin G4-Related Disease, while reiterating an extensive list of clinical, regulatory, financing, operational and geopolitical risks facing the program and the company. An underappreciated aspect of the update is Zenas’s reliance on China-based partners and manufacturers, including WuXi Biologics and InnoCare, which introduces additional supply chain and political...

The Mosaic Company ( NYSE:MOS ) will pay a dividend of $0.22 on the 19th of March. The dividend yield will be 3.2...

Crinetics Pharmaceuticals (CRNX) has been in focus after a Goldman Sachs analyst upgrade that followed positive Phase 2 data for atumelnant in congenital adrenal hyperplasia and encouraging early revenue from newly launched Palsonify. See our latest analysis for Crinetics Pharmaceuticals. The latest move in Crinetics shares, which closed at US$56.43, comes after a string of updates including the Palsonify launch, positive atumelnant data, and a US$350.1m follow on equity raise. The 30 day...

In early January 2026, Kratos Defense & Security Solutions announced that Northrop Grumman was competitively awarded the U.S. Marine Corps’ MUX TACAIR Collaborative Combat Aircraft contract, leveraging Northrop’s Prism autonomy software and mission kits with Kratos’ Valkyrie uncrewed aerial system. This award underscores Northrop Grumman’s role in integrating autonomous, uncrewed platforms with crewed fighters, reinforcing its position in high-end combat air capabilities. We’ll now examine...

Why NNN REIT Might Be On Your Radar Today NNN REIT (NNN) has recently drawn attention after posting annual revenue of US$906.297m and net income of US$391.007m, alongside a business model focused on long term net leases across 3,697 properties. See our latest analysis for NNN REIT. At a share price of US$42.21, NNN REIT has logged a 5.37% 1 month share price return and a 6.78% year to date share price return, while its 11.99% 1 year total shareholder return points to momentum that has...

Earlier this week, Tyler Technologies announced a new agreement with Chesterfield County, Virginia, to become the county’s single payment processing partner, unifying online and in-person payments for nearly 400,000 residents across multiple departments via a cloud-based platform powered by Amazon Web Services. This deal deepens Tyler’s long-running presence in Virginia and highlights how its payments and integration capabilities are being used to simplify complex, fragmented local...

Capri Holdings stock snapshot after recent moves Capri Holdings (CPRI) has been trading around $25.67, with a roughly flat move over the past month, a gain in the past 3 months, and mixed returns across longer time frames. See our latest analysis for Capri Holdings. Recent trading has been a bit softer, with a 7 day share price return of 1.91% and a 90 day share price return of 21.2%. The 1 year total shareholder return of 7.95% contrasts with weaker 3 and 5 year total shareholder returns of...

What TJX Companies (TJX) Offers Investors Right Now TJX Companies (TJX) continues to draw attention as an off price apparel and home fashions retailer with global reach, reporting annual revenue of US$58.98b and net income of US$5.12b. For investors tracking recent performance, the stock shows a 0.7% return over the past month and an 8.6% gain over the past 3 months, with a 1 year total return of 30.2%. See our latest analysis for TJX Companies. At a share price of US$156.16, TJX has seen...

What triggered the latest move in Matson stock? Matson (MATX) drew fresh attention after issuing preliminary Q4 2025 results, providing a steady 2026 outlook for operating income, and detailing recent share repurchases that management presents as a signal of confidence. See our latest analysis for Matson. The preliminary Q4 beat and steady 2026 outlook arrived after a strong run in the share price. A 1 day share price return of 10.65% capped a 90 day share price return of 54.48%, while the 3...